New Trial Shows Effectiveness of BPaL Regimen for Highly Drug-Resistant TB

resisttb
Jul 21, 2021
1 min read

TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure to the drug linezolid. Read Here.

Recent Posts

See All

Open letter: Experts call for urgent expansion of Pretomanid label

Despite trials like TB-PRACTECAL displaying the efficacy of pretomanid in the expanded BPaLM regimen, the EMA only approved for the BPaL...

WHO Accelerator Platform for Novel TB Regimens

The meeting of the WHO Accelerator Platform for Novel TB Regimens will be held on Thursday, 8 May 2025, from 14.00 to 15.30 (CET). Main...

WHO announces landmark changes in treatment of drug-resistant tuberculosis

The WHO released comprehensive guidelines for TB this week and shared important new updates to treatment options for MDR-TB. In...

コメントが読み込まれませんでした。

技術的な問題があったようです。お手数ですが、再度接続するか、ページを再読み込みしてださい。